EUVIMEDEUVIMED entdecken
Crossref

A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment

Howard Greenwood, Samantha Ree, Tim Tinsley, Rachel Roberts, Laura Murray, James Dinsley

Nuclear Future · 09.07.2026 · 22 (4)

DOI: 10.63198/nuclearfuture22448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuclear Future, online erschienen am 10.07.2026. Verfasst von Howard Greenwood und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Greenwood, H., Ree, S., Tinsley, T., Roberts, R., Murray, L., & Dinsley, J. (2026). A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment. Nuclear Future, 22(4). https://doi.org/10.63198/nuclearfuture22448

Vancouver

Greenwood H, Ree S, Tinsley T, Roberts R, Murray L, Dinsley J. A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment. Nuclear Future. 2026;22(4). doi:10.63198/nuclearfuture22448

BibTeX
@article{Greenwood2026,
  author = {Greenwood, Howard and Ree, Samantha and Tinsley, Tim and Roberts, Rachel and Murray, Laura and Dinsley, James},
  title = {A production route for lead-212 for Targeted Alpha Therapy; Using the UK’s nuclear legacy for cancer treatment},
  journal = {Nuclear Future},
  year = {2026},
  volume = {22},
  number = {4},
  doi = {10.63198/nuclearfuture22448}
}
Kostenlos starten →